The incident has become a case study in how drug companies artificially prop up prices of their best-selling drugs
May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week
The production licence of Noida-based pharmaceutical firm Marion Biotech, allegedly linked with the deaths of children in Uzbekistan, has been suspended while the results of its controversial cough syrup are awaited, an Uttar Pradesh drug official said Thursday. A team of central agencies and the Uttar Pradesh drug department had carried out an inspection at the firm's office here on December 29 and taken six more samples for testing. During the inspection, the company representatives could not produce documents related to the production of 'Dok-1 max' cough syrup, prompting the government to order halting of its production immediately, Gautam Buddh Nagar Drug Inspector Vaibhav Babbar said. "The production licence of the firm remains suspended, as was ordered on December 29. Now the suspension order has been issued in writing to the firm on January 10 and has been acknowledged by the firm," Babbar told PTI. On the status of the test results, the officer said the samples were taken
Indian Pharma company Marion Biotech Pvt Ltd has halted the production of cough syrup following allegations by Uzbekistan that at least 18 children died in the country after consuming the medicine.
High raw material prices to put pressure on margins
To launch open offer for another 26%; plans merger with Cohance
'Suven alone has multiple engines of growth across all segments and a strong pipeline of Phase 3 and late Phase 2 molecules'
The first nine patients that they will inject would be legally blind, as they have to prove safety first
The Madhya Pradesh government is leaving no stone unturned to facilitate investment assistance to various sectors
Street remains bullish on India prospects, regulatory headwinds for Goa site continue
In July, the RBI had unveiled a mechanism to settle international transactions in rupee to promote the growth of global trade, with emphasis on exports from India
There are demands to extend production linked incentive (PLI) scheme to more sectors such as certain electronic components, pharma and medical devices, and discussions are underway in the government on these proposals, a senior government official said. Discussions are also going on to bring PLI scheme for toys, furniture, bicycles and containers. The objective of the scheme is to make domestic manufacturing globally competitive, create global champions in manufacturing, boost exports and create jobs. The government last year rolled out the scheme with an outlay of about Rs 2 lakh crore for as many as 14 sectors, including automobiles and auto components, white goods, textiles, advanced chemistry cell (ACC) and speciality steel. "So, from Rs 1.97 lakh crore, there are savings from some sectors. So against those savings, things are being planned. Proposals are under consideration," the official said. Demand for including sectors like certain electronic components, toys, furniture,
Freebies to doctors: Why has the ethical code not been enforced? How has EPFO's equity investment experience been? Are FMCG companies eyeing better margins ahead? What is moonlighting? Answers here
China accounts for about one-fifth of FY22 numbers; 41% surge overall
Centre also proposes to have an expert group on medical devices
During Covid-19, most patients were suffering from high temperatures, and the sales of this brand skyrocketed
A team of more than 20 officers associated with the I-T dept conducted the raids on the pharma company's Race Course Road office
The company has received 99 per cent of votes at the shareholders meeting held on Tuesday, PEL said in a statement
Competitive pressures, high valuations limit upsides for listed lab chains
Pain and fever drug Paracetamol and blood-clot preventing Enoxaparin both post growth rates beyond 20%